The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CYRX | +28.33% | -76.98% | -25.45% | -92% |
| S&P | +18.13% | +110.72% | +16.08% | +483% |
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $45.45M | -21.1% |
| Gross Profit | $18.28M | -12.5% |
| Gross Margin | 40.21% | 3.9% |
| Market Cap | $374.02M | 9.9% |
| Market Cap / Employee | $0.32M | 0.0% |
| Employees | 1.2K | 1.4% |
| Net Income | -$12.01M | 84.6% |
| EBITDA | -$2.32M | 68.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $243.42M | 423.9% |
| Accounts Receivable | $33.41M | -16.8% |
| Inventory | 23 | -2.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $224.21M | -41.7% |
| Short Term Debt | $4.32M | -78.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.79% | 13.5% |
| Return On Invested Capital | -13.05% | -0.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.70M | 1.0% |
| Operating Free Cash Flow | -$7.35M | 8.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.04 | 1.00 | 0.83 | 1.03 | 34.56% |
| Price to Sales | 1.77 | 1.69 | 1.41 | 1.85 | 22.38% |
| Price to Tangible Book Value | 2.56 | 2.46 | 2.09 | 1.91 | -18.08% |
| Enterprise Value to EBITDA | -49.43 | -62.46 | -48.27 | -92.87 | 96.74% |
| Return on Equity | -33.1% | -25.8% | -24.1% | -8.5% | -76.74% |
| Total Debt | $233.37M | $250.70M | $242.67M | $228.52M | -43.52% |
CYRX earnings call for the period ending September 30, 2021.
CYRX earnings call for the period ending March 31, 2020.
CYRX earnings call for the period ending December 31, 2019.
CYRX earnings call for the period ending September 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
